NEW YORK – Life Biosciences has launched a Phase I trial of ER ‑ 100, an epigenetic gene therapy for optic neuropathies, which damage the optic nerve and cause vision loss. St ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results